News | March 16, 2012

Depression Increases Death Risk in Coronary Stent Patients

March 16, 2012 - Depression increases the risk of death in patients who have a coronary stent implanted. After seven years of follow up, depressed patients were 1.5 times more likely to have died than non-depressed patients. The findings were independent of age, gender, clinical characteristics, anxiety and the distressed (Type D) personality.

The research was presented at the 12th Annual Spring Meeting on Cardiovascular Nursing, March 16-17, in Copenhagen, Denmark.

Depression has been associated with poor outcomes in coronary artery disease but previous studies have mainly looked at short-term effects, primarily in patients who have had a myocardial infarction or a coronary bypass operation. The current study (FPN 17) investigated the impact of depression on mortality during a seven-year follow up period in patients treated with percutaneous coronary intervention (PCI).

For the study, 1,234 PCI patients aged 26-90 years (average age 62) from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry completed the Hospital Anxiety and Depression Scale (HADS) to assess depression six months after having a stent implanted. The endpoint was all-cause mortality.

The prevalence of depression was 26.3 percent (324 out of 1234 patients). After seven years there were 187 deaths in total (15.2 percent). The incidence of all-cause mortality in depressed patients was 23.5 percent (76 out of 324 patients) versus 12.2 percent (111 out of 910 patients) in non-depressed patients.

Depression was independently associated with all-cause mortality (hazard ratio=1.56; 95 percent confidence interval [1.03–2.35], p = .035) after adjusting for sociodemographics (age, gender), clinical characteristics, anxiety and the Type D personality. Clinical characteristics included type of stent (drug eluting/bare metal), number of vessels obstructed, body mass index, past cardiac surgery or myocardial infarction, indication for the PCI procedure, coronary risk factors (hypertension, hypercholesterolemia, diabetes, family history of cardiovascular disease, smoking) and cardiac medications (aspirin, ACE inhibitors, beta blockers, calcium antagonists, diuretics, nitrates and statins).

Male gender, older age, and diabetes mellitus were also significantly associated with an increased risk of death after seven years of follow up, whereas statins were associated with a reduced risk. Anxiety and Type D personality had no significant effect on all-cause mortality.

“The main finding is that patients who are depressed after coronary stenting have a worse prognosis,” says lead author Nikki Damen, a Ph.D. student at Tilburg University in the Netherlands. “They die earlier than non-depressed patients.”

The reasons for the finding are under investigation. One possible explanation is that depressed patients may have less healthy lifestyles with regard to smoking, drinking alcohol, physical activity and diet, and may be less likely to take their medications. Another possible explanation is that depression could alter the activity of the sympathetic nervous system, leading to increases in heart rate and blood pressure.

“Doctors and nurses have traditionally focused on medical factors like diabetes or family history of cardiovascular disease when assessing PCI patients’ risk of death, but that’s not the whole picture,” says Damen. “Psychological factors do matter as well, in combination with the medical factors.”

She adds: “More research is needed to determine how to screen for depression in cardiovascular patients, and then how to provide treatment.”

For more information: www.escardio.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now